Opens in a new tab. Answers come from the assistant you choose; check key figures against the report.
Research report · November 2026
By Arne Smolders, Founder & CEO, AcademicLabs · Published 10 November 2026 · Data as of 8 November 2026
What minoxidil, pyrimidine-oxide and potassium channel opener patents protect, who develops and sells, what the news, science and public funding say, and where the open space is. Built from nine AcademicLabs datasets, from patents and companies to every alopecia trial on record and six years of clinical outcome papers: a recent, relevant subset of each was read record by record by AcademicLabs AI and cross-analysed across sources.
Patents 4,148 2,146 relevant · 3 searches Companies 2,210 579 relevant · 56 countries News 2,007 571 relevant · 228 events Publications 861 346 relevant · 2026 Funded projects 1,177 106 relevant · since 2022 Clinical papers 1,174 448 relevant · 2020 to 2026 Trials, all years 1,954 1,515 relevant · all alopecia Trials 2026+ 1,453 72 relevant · starting 2026+ Researchers 110 29 relevant · h-index over 75The question behind every view: what will someone losing their hair be treated with by 2030, and who will supply it?
Horizon 1 · Today Minoxidil and finasteride, reformulated 373 inventions, 5 new molecules; solid evidence only for the basics
Horizon 2 · 2027 to 2028 Better versions arrive An approved minoxidil pill, scalp-only blockers, women's programs
Horizon 3 · 2029 and later New biology wakes dormant roots Six new mechanisms in humans, after nine that stalled
What it means Where to play, and for whom Nine sources side by side, opportunities, the patient view
| Dataset | Topic searched | Scope | Records | Relevant |
|---|---|---|---|---|
| Patents | Minoxidil and its analogs by drug and chemical name; potassium channel openers; openers combined with hair terms | Published 2012 to 2026 (minoxidil), 2019 to 2026 (openers), all years (openers with hair terms) | 4,148 | 2,146 |
| Companies | Minoxidil or potassium channel opener activity; outside the US, minoxidil with hair terms or hair-loss drug development | United States and 55 other countries; active companies; pharmacies excluded | 2,210 | 579 |
| News | Minoxidil and its analogs, hair loss, hair growth and hair biology | Last 12 months | 2,007 | 571 |
| Publications | Minoxidil and its analogs, hair loss, hair growth and hair biology, in the title | PubMed; 2026; research papers (reviews and letters excluded) | 861 | 346 |
| Funded projects | Minoxidil and its analogs, hair loss, hair growth and hair biology | Starting 2022 or later | 1,177 | 106 |
| Clinical trials, new | Minoxidil and its analogs, hair loss and hair growth | Treatment trials starting 2026 to 2030 | 1,453 | 72 |
Each dataset is a recent, relevant subset rather than everything ever published. AcademicLabs AI read every record and judged its relevance before the analysis.
Overview
Summary
75% It is a minoxidil landscape, not an analogs landscape. Minoxidil itself is central in 279 of 373 core inventions. Aminexil appears in 7, minoxidil sulfate in 1, and only 5 claim a new chemical entity.
77% Innovation is reformulation and combination. 177 inventions are formulation or delivery systems and 113 are combinations of actives. Finasteride is the most common partner (76 inventions). Taisho and Rohto have refined the topical almost every year for 15 years.
88% Claims carry little evidence. 88% of core inventions mention no supporting data in abstract or claims, and none report human testing there. Differentiation will be won in clinic, not in claim language.
93% vs 55% The weaker the control, the better the result. Of 205 hair-treatment outcome papers since 2020, 93% of uncontrolled studies report benefit, against 55% of randomized trials and 46% of those tested against an active treatment. PRP, exosomes and devices live in the uncontrolled zone: 6%, 9% and 8% of their trials are placebo-controlled.
0 of 4 The pill does not grow more hair than the liquid. In four published head-to-heads, low-dose oral minoxidil (0.25 to 5 mg) never beat topical minoxidil on hair density, and only 1 of 22 oral minoxidil papers in 2026 is a randomized trial. VDPHL01 doses higher (8.5 mg extended release, up to twice daily) and reached +43.9 hairs/cm² at 12 months, but is tested only against placebo: whether it beats the liquid is the open question.
0 of 252 Channels, not patent holders, sell minoxidil. Across 579 relevant companies worldwide, none of the 252 telehealth, pharmacy, compounding and clinic players holds a patent here, while 30 of 36 minoxidil developers do. Oral minoxidil is already offered by 47 channels and sold as branded tablets in India.
21% vs 1% Who invents is not who tests. The US holds 40% of minoxidil inventions and leads 42% of company trials. India leads 21% of all alopecia trials and the Middle East and Africa 16%, with 1% and 2% of inventions. Europe and South Korea hold 46% of hair-loss drug developers: the partnering pool.
33 vs 15 Citation fame is not minoxidil expertise. Eight practice leaders (NYU, Lahey, Mass General Brigham, Sinclair, Bologna, Yale, Kyorin) published 33 minoxidil papers in 2026; the 29 top-cited hair researchers published 15. Hair is about three quarters of the leaders' output and 6% of the top-cited group's.
109 One company is fencing oral minoxidil. VeraDermics filed 109 applications (103 in the US) on a single modified-release oral minoxidil invention, 15% of all core filings, with patent term to 2043. Its VDPHL01 hit Phase 3 endpoints in October 2026, and 12-month data in November showed gains holding or growing with continued use.
4 → 33 Oral minoxidil is the fastest-growing trial category, with no agreed dose. Trials rose from 4 in 2010–19 to 33 since 2023, mostly investigator-led in India, Iran and Brazil. Doses run from 0.25 to 10 mg and 20 of 42 trials state none: the first approved pill will set the standard.
2024–26 Topical antiandrogens are pairing up with minoxidil. Cosmo (clascoterone, positive 12-month Phase 3) and Kintor (pyrilutamide, pivotal Phase 3 endpoint met in Mar 2026) filed minoxidil combinations as their own antiandrogens neared filing.
123 Minoxidil is the benchmark everyone tests against. It is the comparator in 123 of 684 pattern-hair-loss trials on record, and in 9 of the 16 minoxidil trials starting from 2026. The only new oral entries are Eurofarma's two Phase 3 trials (men and women, from 2027) and a sublingual dose-ranging Phase 2.
17% Women are falling behind in trials. Only 17% of pattern-hair-loss trials starting since 2023 enrol women only, down from 30% in 2016–19. VeraDermics' 556-woman Phase 3, Eurofarma's MINORA-WOMEN and Pelage's female PP405 study are the openings.
9 Twenty years of new mechanisms, no filing. Nine new mechanisms for pattern hair loss entered trials from 2007 to 2020, from Wnt activation and prostaglandins to peptides and cell injections; none reached a filing. The new wave (PP405, two prolactin receptor antibodies, a thyroid mimetic) targets better-validated biology but must clear the same bar.
80% Alopecia areata shows what success looks like, and the catch. JAK inhibitors went from case reports in 2014 to four approved drugs; 21% to 55% of patients regain most hair vs 1% to 9% on placebo. But 80% of responders relapse after stopping. Hair drugs are maintenance therapies, so convenience and long-term safety decide the market.
6 of 565 Hair is an orphan use for potassium channel openers. Of 565 relevant opener patents since 2019, only 6 propose a hair use; 46% target Kv7 channels for brain disorders. Hair-linked opener chemistry peaked in 2006–08 and 45 of 54 such patents predate 2010.
0 Every source confirms the potassium channel gap. Across $37.5 million of public grants, one ~$28,000 project studies KATP channels in the follicle. No 2026 paper tests channel subtypes or SULT1A1 response, no news event mentions either, and none of the 1,515 alopecia trials tests a new opener.
23 → 51 Scarring alopecia is a trial frontier without patents. Scarring alopecia trials more than doubled (2016–19 vs 2023–27), testing JAK, TYK2, IL-31 and even GLP-1 drugs, nearly all investigator-led. Only 2 of 373 minoxidil inventions mention a scarring form.
1 · Today
Horizon 1 · Today's standard
What is invented and protected, who files and where, who sells it, and how well today's treatments actually work.
373 core minoxidil inventions
5 claim a new molecule
36 companies develop minoxidil products
1 of 22 oral minoxidil papers in 2026 is a randomized trial
93% vs 55% of uncontrolled vs randomized studies report benefit
21% vs 1% India's share of alopecia trials vs minoxidil inventions
What is protected
Innovation themes
Each invention can carry several themes, tagged from its claims and AI summary. Shading shows a theme's share of that period's inventions, so periods of different size compare fairly.
| Theme | ≤2011 n=37 | 2012–16 n=126 | 2017–21 n=115 | 2022–26 n=95 | All | Trend |
|---|---|---|---|---|---|---|
| Vehicle, solubility & stability (incl. PG-free) | 14 | 47 | 44 | 30 | 135 | ▼ cooling |
| Antiandrogen combinations | 10 | 36 | 27 | 32 | 105 | ▲ rising |
| Botanicals, peptides & cosmetic actives | 6 | 22 | 28 | 14 | 70 | ▼ cooling |
| Devices: microneedling, light, energy | 9 | 17 | 20 | 15 | 61 | ■ steady |
| Advanced delivery carriers | 4 | 16 | 16 | 11 | 47 | ■ steady |
| Oral / systemic minoxidil | 4 | 16 | 7 | 18 | 45 | ▲ rising |
Activity over time
New core inventions have held at roughly 15–40 a year since 2011. The 2025–26 spike in filings is almost entirely VeraDermics continuations. Recent years are understated because applications publish about 18 months after filing.
Who files
Two rankings tell different stories. By inventions, Japanese OTC players and Follea lead. By filings, VeraDermics dwarfs everyone because it files many applications per invention. The timeline shows when each applicant was active and how hard it filed.
Companies · global
AcademicLabs company searches matched 2,210 companies on minoxidil, hair-loss and opener terms in the US and 55 other countries. 644 passed the AI pre-screen and were analysed in depth; after review, 579 are relevant players. Read against the patents, they split into inventors, late-stage developers, brand owners, channels and suppliers, with clear regional patterns.
| Segment | Companies | Minoxidil-based offer | Hold patents | Named partner |
|---|---|---|---|---|
| Clinics, CROs & services | 140 | 33 | 0 | 6 |
| Non-minoxidil hair pipeline | 119 | 4 | 21 | 18 |
| Telehealth, pharmacy & compounding channels | 112 | 45 | 0 | 0 |
| Consumer hair brands | 66 | 8 | 2 | 2 |
| Suppliers & manufacturers | 38 | 12 | 2 | 2 |
| Minoxidil developers & IP holders | 36 | 36 | 30 | 8 |
| Segment | Europe n=149 | US n=140 | India n=97 | South Korea n=29 | Japan n=25 | Greater China n=22 | Canada n=32 | SE & S Asia n=25 | Middle East & Africa n=30 | Latin America n=17 | Australia n=13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Minoxidil developers & IP holders | 7 | 14 | 1 | 5 | 2 | 1 | 1 | 1 | 4 | ||
| Non-minoxidil hair pipeline | 42 | 12 | 7 | 17 | 16 | 13 | 6 | 2 | 3 | 1 | |
| Minoxidil brand marketers (pharma & OTC) | 1 | 20 | 2 | 2 | 1 | ||||||
| Potassium channel players outside hair | 27 | ||||||||||
| Suppliers & manufacturers | 10 | 12 | 7 | 1 | 2 | 5 | 1 | ||||
| Telehealth, pharmacy & compounding channels | 41 | 20 | 9 | 1 | 1 | 9 | 10 | 7 | 7 | 7 |
30 of the 36 minoxidil developers hold patents in this landscape. None of the 112 telehealth, pharmacy and compounding channels or the 140 clinics and CROs does. For a branded product, channels are partners, not licensors.
Besides VeraDermics, Samson Clinical (sublingual SAM-002, Phase 3), Eurofarma (oral N1087, Phase 3) and Business Life Health (oral versus sublingual) are in late-stage trials. In India at least 6 pharma brands already sell minoxidil tablets, and 47 of the 112 channels worldwide offer oral minoxidil.
Kintor's KX-826 met its pivotal Phase 3 endpoint in Mar 2026 with a China filing planned, and Cosmo reported positive 12-month Phase 3 data for clascoterone. Both already hold minoxidil-combination patents. Chong Kun Dang (sustained-release dutasteride, Phase 3) and OliX (androgen receptor RNAi) follow.
South Korea, Japan and Greater China host 46 of the 119 companies developing non-minoxidil hair therapies, Europe 42 and the US 12. Cell, exosome and secretome approaches are the largest named group, ahead of immune pathways for alopecia areata and androgen receptor blockers.
20 of the 26 pharma and OTC companies marketing minoxidil brands are Indian (Cipla's Tugain, Dr Reddy's Mintop, Intas, Glenmark, Alkem). Cipla reports about ₹35 crore in annual Tugain sales, and Glenmark launched its minoxidil foam in Canada in Mar 2026. These are channel and price benchmarks for emerging markets.
Of 155 minoxidil developers and pipeline companies, 26 name a partner and only 12 say they seek one. They include Samson Clinical, AnHorn (AH-001), Triple Hair, Bionanoplus, Follicum, Caring Brands and Aneira.
Hair-loss assets in Phase 2 or later, or marketed, grouped by approach.
| Company | Asset | Stage | Partner status |
|---|---|---|---|
| Minoxidil, new forms and combinations 6 companies | |||
| VeraDermics United States | VDPHL01, extended-release oral minoxidil | Phase 3; Study 304 met endpoints (Oct 2026); 12-month Study 302 positive (Nov 2026) | None identified |
| Samson Clinical United Kingdom | SAM-002, sublingual minoxidil tablet | Phase 3; pivotal trial started 2025 | None named; seeks pharma, distribution and licensing partners |
| Eurofarma Brazil | N1087 oral minoxidil; minoxidil foam | Phase 3 | None named |
| Business Life Health Brazil | Oral versus sublingual minoxidil | Phase 3 trial (started 2023) | None named |
| Triple Hair Canada | TH07, topical minoxidil, finasteride and latanoprost | Phase 3; first patient dosed Apr 2026 | Aché, Akums, Mother's Pharmaceutical |
| Mechanism | Europe n=42 | South Korea n=17 | Japan n=16 | Greater China n=13 | US n=12 | India n=7 | Canada n=6 | Other regions n=6 |
|---|---|---|---|---|---|---|---|---|
| Cells, stem cells, exosomes & secretomes | 4 | 3 | 1 | 5 | 4 | 3 | 2 | |
| JAK & immune pathways | 5 | 2 | 1 | 3 | 2 | 3 | 1 | 1 |
| Androgen receptor & 5-alpha-reductase | 7 | 4 | 1 | 3 | 1 | |||
| Thyroid, peptides, growth factors & Wnt | 5 | 3 | 3 | 1 | 1 | |||
| Botanicals & microbiome | 2 | 3 | 2 | 1 | 1 | 1 | ||
| Prostaglandin analogs | 2 | 1 |
Companies with no named partner come first; partnered or inactive ones follow as validation and signal limited availability.
| Company | Program | Stage | Patents | Partner status | Reason to contact |
|---|---|---|---|---|---|
| No named partner the focus | |||||
| VeraDermics Connecticut | VDPHL01, extended-release oral minoxidil | Phase 3; Study 304 met endpoints (Oct 2026); 12-month Study 302 positive (Nov 2026) | 109 | None identified | The one US late-stage minoxidil asset; ex-US rights or co-commercialization are the natural questions. |
| Samson Clinical United Kingdom | SAM-002, sublingual minoxidil | Phase 3 | 15 | None named; seeks pharma, distribution and licensing partners | Late-stage alternative to oral minoxidil that is actively looking for partners. |
| Kintor China | KX-826 topical antiandrogen plus minoxidil-combination IP | Phase 3 endpoint met; China filing planned | 5 | None named | Near-approval antiandrogen; ex-China rights and the minoxidil combination are open questions. |
| Cosmo / Cassiopea Luxembourg | Clascoterone 5% topical plus minoxidil-combination IP | Phase 3 positive; US filing planned early 2027 | 4 | No commercial partner named | Combination patents make it a natural minoxidil partner. |
| Eurofarma Brazil | N1087 oral minoxidil; minoxidil foam | Phase 3 | 3 | None named | Latin American oral minoxidil developer with commercial scale. |
579 companies
| Company | Segment | What it does | Stage | Patents |
|---|---|---|---|---|
| VeraDermics Connecticut | Minoxidil developers & IP holders | VeraDermics develops extended-release oral minoxidil to promote hair regrowth in women and men with pattern hair loss. | Phase 3 | 109 |
| Taisho Pharmaceutical Co Ltd Japan | Minoxidil developers & IP holders | Taisho sells RiUP minoxidil and researches topical formulations and follicular delivery to improve hair growth. named partner | Marketed as cosmetic or OTC product | 89 |
| Johnson & Johnson New Jersey | Minoxidil developers & IP holders | Johnson & Johnson patented minoxidil formulations for hair growth and published preclinical Kv7-opener research for epilepsy. | 66 | |
| Aneira Pharma California | Minoxidil developers & IP holders | Aneira Pharma develops a patented minoxidil–latanoprost combination intended to promote hair growth and prevent hair loss. seeks partners | 25 | |
| Samson Clinical United Kingdom | Minoxidil developers & IP holders | Samson Clinical develops a rapid-dissolving sublingual minoxidil tablet intended to improve hair growth and reduce systemic side effects. seeks partners | Phase 3 | 15 |
Regions · who invents, develops, tests and publishes
Raw volumes do not compare across datasets: a patent family, a company and a trial are different units, and each search had its own scope. Each region's share of every dataset does compare, and it reveals four distinct roles.
| Region | Patents | Companies | Trials | Industry trials | Clinical papers |
|---|---|---|---|---|---|
| United States | 40% | 17% | 23% | 42% | 17% |
| Europe | 21% | 32% | 11% | 16% | 21% |
| Japan | 13% | 12% | 3% | 4% | 4% |
| South Korea | 6% | 14% | 2% | 4% | 3% |
| Greater China | 6% | 9% | 12% | 6% | 13% |
| India | 1% | 5% | 21% | 15% | 8% |
The US holds 40% of minoxidil inventions and leads 42% of company-sponsored trials. Japan holds 13% of inventions (Taisho, Rohto, Kyushu University, Nissan Chemical) but leads 3% of trials.
Together 46% of hair-loss drug developers but 27% of inventions. Many build on molecules others patented, or license them: the partnering pool.
India leads 21% of all alopecia trials and the Middle East and Africa 16%, mostly investigator-led tests of PRP, supplements, generic JAK inhibitors and oral minoxidil. They hold 1% and 2% of inventions.
From 1% of trials before 2016 to 11% since 2023, 13% of clinical papers and more than a third of all 2026 hair papers. Its 6% patent share will grow as AcademicLabs adds Chinese patent offices.
Science · publications 2026
861 publications from 2026 screened, 346 relevant to hair-loss treatment. Each was classified by design, treatment, size, safety finding and author affiliation.
346 relevant publications
25 randomized trials
145 lab and animal studies
22 on oral or sublingual minoxidil
0 test SULT1A1 response
0 test K-channel subtypes
Academic evidence, 2026 papers
1
Randomized trial Sublingual minoxidil in transgender men on testosterone, 11 to 50 participants
1
Prospective, non-randomized Frontal fibrosing alopecia, 11 to 50 participants
7
Retrospective cohorts Dosing time, combination with spironolactone, lab safety
4
Surveys and case series Quality of life, children, bridging therapy
9
Reviews, consensus and letters Consensus recommendations, safety letters
Industry trials
VeraDermics · VDPHL01 Phase 3 Study 304536 men; both co-primary endpoints met (Oct 2026); Study 302 at 12 months positive (Nov 2026)
VeraDermics · VDPHL01 Phase 2 Study 207Women with pattern hair loss; results discussed Jul 2026
Samson Clinical · SAM-002 sublingual, Phase 3Enrolment complete Nov 2025; last patient, last visit May 2026
Eurofarma · N1087 oral minoxidil, Phase 3Brazil
Business Life Health · Oral vs sublingual, Phase 3Brazil, started 2023
Academic evidence: the 22 publications from 2026 on oral or sublingual minoxidil, by evidence level. Industry trials: as reported in news and company profiles. The only randomized trial is small and in a niche population.Institutions with the most relevant 2026 papers, with their oral minoxidil output and links to the patent record.
| Institution | Papers | Oral minoxidil | Focus | Key people | Patent link | Paper to read |
|---|---|---|---|---|---|---|
| NYU Langone | 11 | 7 | Low-dose oral minoxidil dosing and response | Jerry Shapiro, Kristen Lo Sicco, Archie Spindler | None found | Increased efficacy of daytime low-dose oral minoxidil dosing |
| Mass General Brigham | 10 | 2 | Alopecia areata (JAK); LDOM safety in women | Arash Mostaghimi | None found | Safety of combination spironolactone and LDOM in women |
| Lahey Hospital | 7 | 2 | Alopecia areata; oral versus topical minoxidil | Maryanne Senna | None found | Oral and topical minoxidil in female pattern hair loss |
| Sinclair Dermatology, Melbourne | 7 | 2 | Sublingual minoxidil; finasteride tapering | Rodney Sinclair, Bevin Bhoyrul | Sinclair is an inventor on Samson Clinical filings | Sublingual minoxidil randomized trial |
| University of Bologna and Sant'Orsola | 10 | 0 | Alopecia areata (JAK); topical finasteride | Bianca Maria Piraccini, Michela Starace | None found | Topical finasteride for male pattern hair loss: real-world data |
| Central South University | 9 | 0 | Alopecia areata (JAK); single-cell biology of pattern loss | Wei Shi, Ji Li | None found | Single-cell transcriptomics of male androgenetic alopecia |
Clinical evidence · what works today
1,174 clinical-study publications on alopecia from 2020 to 2026 were screened; 209 test a hair-loss treatment against a hair outcome. Read together with the 1,515-trial record, they show which treatments rest on solid evidence, and how study design shapes what gets reported.
205 outcome studies with a verdict
148 of them randomized
93% of uncontrolled studies report benefit
55% of randomized trials do
46% when tested against an active treatment
0 head-to-head trials where an oral minoxidil dose beat the liquid
| Treatment | Evidence | Trials | Placebo-controlled | Papers | Report benefit | What the best data show |
|---|---|---|---|---|---|---|
| Pattern hair loss · approved basics | ||||||
| Finasteride and dutasteride | Strong | 84 | 33% | 9 | 67% | Topical finasteride spray: +20.2 vs +6.7 hairs at 24 weeks in a Phase 3, close to the oral pill. Finasteride and dutasteride tied head to head (2026). Source |
| Topical minoxidil | Strong | 91 | 14% | 23 | 65% | Approved since 1988 and now mostly the yardstick: the comparator in 123 pattern-hair-loss trials. Add-ons beat it in small open trials. |
| Pattern hair loss · arriving | ||||||
| Oral minoxidil | Moderate | 42 | 17% | 7 | 29% | A 5 mg pill matched 5% liquid on hair density at 24 weeks (JAMA Dermatology 2024). Against placebo, VDPHL01 added +28.6 to +36.4 vs +6.6 hairs/cm² in Phase 3 (Oct 2026), and reached +43.9 at 12 months on twice daily (Nov 2026). Source |
| Topical antiandrogens | Moderate | 15 | 93% | · | too few | Clascoterone and pyrilutamide met Phase 3 endpoints in 2026; Kintor's AR degrader GT20029 beat placebo at 12 weeks in Phase 2. Source |
Experts · top-cited researchers with 2026 hair papers
110 researchers with an h-index above 75 and a 2026 hair publication. AcademicLabs AI screened their profiles and analysed the relevant ones in depth. 29 have sustained hair research; the people who actually generate minoxidil evidence mostly sit below this citation cut-off. The clinical-study record confirms who runs the trials: since 2020, Brett King (Yale) co-authored 22 outcome papers, mostly on JAK inhibitors, Rodney Sinclair 19 and Bianca Maria Piraccini 13.
110 top-cited researchers
29 with sustained hair research
6% median hair share of their papers
0 study potassium channels in hair
12 name industry ties
| Expert | Relevant expertise | Hair papers 2026 | Treatment 2026 | Minoxidil 2026 | Hair share 2022 to 2026 | Minoxidil 2022 to 2026 | Clinical papers 2020–26 | Trials | Patents |
|---|---|---|---|---|---|---|---|---|---|
| Practice leaders from the publication and trial data 9 people · 134 hair papers in 2026 · 33 on minoxidil | |||||||||
| Jerry Shapiro * New York University | Low-dose oral minoxidil dosing and response; pattern hair loss | 33 | 24 | 13 | 90% | 45 | 9 | 6 | |
| Bianca Maria Piraccini University of Bologna | Alopecia areata JAK therapy; topical finasteride real-world data | 26 | 18 | 3 | 39% | 19 | 13 | ||
| Maryanne M. Senna Lahey Hospital | Alopecia areata and frontal fibrosing alopecia trials; oral versus topical minoxidil | 19 | 10 | 5 | 90% | 14 | 8 | 3 | |
| Rodney Sinclair * Sinclair Dermatology | Sublingual minoxidil trials; antiandrogens and finasteride tapering | 17 | 15 | 5 | 78% | 36 | 19 | 7 | 15 |
| Arash Mostaghimi Mass General Brigham | Alopecia areata JAK outcomes; spironolactone plus oral minoxidil safety | 13 | 9 | 3 | 38% | 14 | 5 | ||
| Researcher | Named companies | Most relevant to |
|---|---|---|
| Ralf Paus | QIMA Limited, Giuliani, 21c Consultancy | Alopecia areata drug developers, Pattern hair loss drug developers, Cosmetic hair care companies |
| Angela M. Christiano | Xencor | Alopecia areata drug developers |
| Aditya K. Gupta | Mediprobe Research Inc. | Pattern hair loss drug developers, Oral minoxidil developers |
| Mario E. Lacouture | BPGbio, Canfield Scientific Inc | Oral minoxidil developers |
| Emma Guttman-Yassky | Regeneron, Pfizer, AbbVie, LEO Pharma, Sun Pharma | Alopecia areata drug developers |
| Jacek C. Szepietowski | Bristol-Myers Squibb, Nektar Therapeutics, Pfizer | Alopecia areata drug developers |
2 · Next wave
Horizon 2 · The next wave, 2027 to 2028
Late-stage programs that make today's medicines easier and safer to use: an approved minoxidil pill, hormone blockers that act only in the scalp, and the first programs designed for women. The trial record shows how the evidence for them is being built.
3 oral or sublingual minoxidil programs in Phase 3
2 scalp-only hormone blockers with positive Phase 3
4 → 33 oral minoxidil trials, 2010–19 vs 2023–27
9 of 16 new trials use minoxidil as the comparator
$256M VeraDermics IPO, the year's largest financing
3 programs now designed for women
Trial landscape · every alopecia trial on record
Every clinical trial mentioning alopecia, all years and registries: 1,954 records, of which AcademicLabs AI kept 1,515 that study a hair-loss condition. 954 started in 2020 or later.
1,515 alopecia trials analysed
107 → 283 pattern hair loss trials, 2016–19 vs 2023–27
75 → 186 alopecia areata trials, same periods
4 → 33 oral minoxidil trials, 2010–19 vs 2023–27
19% of interventional trials are placebo-controlled
29% are company-sponsored
| Treatment | Pattern hair loss | Alopecia areata | Scarring | Treatment-induced |
|---|---|---|---|---|
| Supplements and cosmetics | 80 | 45 | 12 | 8 |
| JAK inhibitor | 2 | 101 | 11 | · |
| PRP and blood products | 65 | 12 | 11 | 1 |
| Topical minoxidil | 79 | 10 | · | 2 |
| Cells, exosomes, fat | 68 | 6 | 6 | · |
| Laser and light | 46 | 19 | 8 | 6 |
Trial design · how the evidence is built
How trials are designed decides what they can prove. Drug classes with company sponsors are tested against placebo in large trials; procedures and add-ons are tested in small, open, investigator-led studies, which is why their evidence stays mixed.
| Who is studied | ≤2015 | 2016–19 | 2020–22 | 2023–27 |
|---|---|---|---|---|
| Pattern hair loss: men only | 53% | 38% | 38% | 34% |
| Pattern hair loss: women only | 19% | 30% | 20% | 17% |
| Alopecia areata: incl. children | 5% | 11% | 8% | 17% |
| Treatment | US | India | Iran | China | Egypt | Thailand | Japan | Netherlands |
|---|---|---|---|---|---|---|---|---|
| JAK inhibitor | 55 | 27 | 2 | 11 | 2 | 2 | · | · |
| Biologic or antibody | 19 | · | 1 | 1 | · | · | 1 | · |
| Other drugs, incl. new molecules | 34 | 7 | 7 | 8 | 9 | 1 | 6 | · |
| Oral minoxidil | 5 | 10 | 5 | · | · | 1 | · | · |
| Topical minoxidil | 13 | 21 | 14 | 15 | 4 | 3 | · | · |
| Hormonal: 5-ARI or antiandrogen | 6 | 10 | 14 | 7 | 1 | 6 | 1 | · |
Only 17% of pattern-hair-loss trials starting since 2023 enrol women only, down from 30% in 2016–19, although women make up a large share of patients. Eurofarma, VeraDermics and Pelage are the exceptions.
17% of alopecia areata trials since 2023 include adolescents or children, up from 5% before 2016, as JAK makers extend labels (baricitinib reached adolescents in Sept 2026).
The US led 29% of trials up to 2015 and 17% since 2023; India now leads 22%, China 11%. Cheap investigator trials answer practical questions; regulators still rely on company trials.
309 interventional trials test two or more modalities, usually minoxidil plus a procedure. None has led to an approved combination product, which leaves room for a developer to run the definitive trial.
Clinical trials · starting 2026 to 2030
1,453 treatment trials matched the broad hair query. AcademicLabs AI kept 72 that are about hair, minoxidil or potassium channel openers. Of the rest, 833 are cancer trials and 706 mention alopecia only in passing, typically as a side effect.
72 hair-relevant trials
16 include minoxidil
9 use it as the comparator
9 in scarring alopecia
1 other opener (nicorandil, heart attack)
4 already withdrawn
| Condition | Not phased (other) | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | All |
|---|---|---|---|---|---|---|---|---|
| Pattern hair loss | 11 | 2 | 4 | 5 | 3 | 6 | 1 | 32 |
| Alopecia areata | 2 | 2 | · | 3 | · | 3 | 3 | 13 |
| Scarring alopecia | 1 | · | · | 6 | 1 | · | 1 | 9 |
| Chemotherapy hair loss | 1 | 2 | · | · | · | · | · | 3 |
| Scalp, other hair | 5 | 1 | · | · | · | 1 | 1 | 8 |
| Not hair (minoxidil or opener elsewhere) | 2 | 1 | · | 1 | · | 2 | 1 | 7 |
Eurofarma registered two Phase 3 trials of its oral minoxidil N1087 from January 2027, one in men and one in women (MINORA-WOMEN, titrating 0.5 to 2 mg). Rodney Sinclair's sublingual dose-ranging Phase 2 started in February 2026. With Pelage's PP405 female Phase 2, women are becoming the next battleground.
9 trials, almost all investigator-led repurposing: brepocitinib (Priovant, Phase 2/3, the only industry sponsor), deucravacitinib, delgocitinib, upadacitinib, nemolizumab, and even tirzepatide in central centrifugal cicatricial alopecia. Only 2 of 373 minoxidil inventions mention a scarring form.
Beyond minoxidil, the only potassium channel opener in a 2026 trial is nicorandil for heart attack. Duke is testing topical minoxidil to improve blood flow in breast-reconstruction skin flaps: proof that the vasodilator is being repurposed, but not by hair developers.
Applied Biology holds 10 minoxidil filings (31 together with its partner Follea) and registered 5 trials, yet 3 are already withdrawn and no news event mentions it. The same footprint view flags who executes and who only files.
1,515 trials
| Start | Trial | Condition · treatment | Phase · status |
|---|---|---|---|
| · | A Phase 2, Multicenter, Prospective, Randomized, Cassiopea · Italy | Pattern hair loss Hormonal: 5-ARI or antiandrogen | Phase 2 Unknown |
| · | A Study to Explore the Effect of Controlled Cutaneous Perturbation and Pharmacologic Modulation for Inducing Follicular Neogenesis nan | Pattern hair loss Laser and light | No phase Unknown |
| · | Expanded Access to Upadacitinib AbbVie | Alopecia areata JAK inhibitor | No phase Unknown |
| · | Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600) Pfizer · United States | Alopecia areata JAK inhibitor | No phase Unknown |
| · | A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Chil Pfizer · United States | Alopecia areata JAK inhibitor | Phase 1 Unknown |
Market signals · news, Nov 2025 to Nov 2026
2,007 news articles from the last 12 months, each read by AcademicLabs AI. 571 were relevant and collapse into 228 distinct events once duplicate coverage is merged.
228 distinct events
48 clinical readouts
19 financings
17 deals and M&A
7 approvals
0 on compounded minoxidil rules
228 events
| Date | Event | Type |
|---|---|---|
| 2026-11-04 | On November 4, 2026, Q32 Bio reported Q3 results and said it was advancing bempikibart toward Phase 3 testing in alopecia areata, signaling potential progress toward a pivotal-stage hair-loss treatment but no change in patient access. | Trial start or stage change Other drugs (mostly alopecia areata) |
| 2026-11-04 | On November 4, 2026, Q32 Bio reported Phase 2a bempikibart results in severe alopecia areata showing responses at Week 36 and durability after treatment stopped, supporting plans to begin a registration-directed program in 1H 2027. | Clinical readout Other drugs (mostly alopecia areata) |
| 2026-11-03 | On November 3, 2026, Este Medical Group launched a UK hair-restoration pathway for transgender and female patients, expanding access to personalised assessment and surgical procedures at its Birmingham clinic. | Product launch Devices and procedures |
| 2026-11-03 | On 3 November 2026, an article described combing-triggered electrostimulation synchronized with deep delivery for rapid hair regrowth in androgenetic alopecia, highlighting a potential device-based treatment approach but providing no evidence of a route to patients. | Other Devices and procedures |
| 2026-11-02 | On 2 November 2026, an article was published comparing oral dutasteride 0.5 mg plus oral minoxidil 2.5 mg with either drug alone in male androgenetic alopecia; it may inform the combination’s competitive positioning, but the supplied text gives no results. | Other Combinations |
3 · Step change
Horizon 3 · The step change, 2029 and later
The treatments that could do more than protect weakening roots. They are in early human testing or still in the lab, two promising directions have no one working on them, and nine earlier attempts stalled.
6 new mechanisms in human testing
$220M raised by Pelage and Absci since late 2025
9 earlier new mechanisms stalled, 2007 to 2020
80% of JAK responders relapse after stopping
22 vs 0 responder-test patents versus independent validation studies
0 hair-selective potassium channel openers in development
New mechanisms · what could change the game
Hair-loss programs placed by how far they have come and how new their biology is. The top row is where a real step change could come from.
Pelage's topical aims to restart sleeping hair stem cells, which today's drugs cannot do. Positive Phase 2, $120 million raised, and Phase 2/3 dosing began in October 2026, with a female study too. The strongest step-change signal.
Absci's antibody blocks prolactin signalling in the scalp. Phase 1/2a showed early safety and a 65-day half-life, pointing to infrequent dosing; Absci raised $100 million in June 2026. The trial record shows it is not alone: Hope Medicine's HMI-115 hits the same receptor and completed a Phase 2 in men in 2023.
Rubedo's RLS-1496 (cell-stress pathway) entered human testing in October 2026; TechnoDerma's topical thyroid-mimetic reported hair growth in Phase 2a.
EU and UK grants fund artificial and cell-produced hair follicles (Geneus and Biofabics, HairClone). The long-term route to replacing transplants, still preclinical.
A test that predicts who responds to minoxidil (22 patents; the only trials come from the patent holder) and a hair-selective potassium channel opener (no program, though Cantú syndrome proves the target can drive strong hair growth).
In alopecia areata, biology-based drugs went from none to three approved JAK inhibitors; Nektar heads to Phase 3 and argenx is buying Forte for about $2.2 billion. Serious pharma money is now in hair.
Lessons · alopecia areata and twenty years of attempts
Alopecia areata shows the path: a repurposed drug class went from case reports in 2014 to four approved drugs by 2026. Pattern hair loss shows the risk: nine new mechanisms entered trials between 2007 and 2020, and none reached a filing.
Wnt activation, prostaglandins, peptides and cell injections all chased hair growth in general. Most reported modest Phase 2 gains on surrogate endpoints and never ran the large hair-count trial regulators expect.
The new wave targets biology with human validation: hormone signalling in the scalp (prolactin receptor antibodies from Hope Medicine and Absci), dormant stem cells (PP405) and thyroid signalling. Two prolactin receptor programs now compete for the same idea.
Topical minoxidil and oral finasteride set the yardstick; the oral minoxidil pill will raise it in 2027 to 2028. A new mechanism must beat that, or add to it, in 6 to 12-month trials with hair counts, against placebo and ideally against minoxidil.
Beyond minoxidil · potassium channel openers
Two extra searches cover the first half of the brief: potassium channel openers in general (2019–2026) and openers combined with hair terms (all years). Opener R&D has moved to the brain and metabolism. The KATP channel minoxidil acts on is now mostly developed for rare metabolic and cardiopulmonary disease.
The same channel family as minoxidil, developed for other diseases. These are the companies with clinical KATP know-how, safety data and chemistry that could transfer to hair.
| Owner | Asset or chemistry | Use in patents | Stage | Filings | Why it matters for hair |
|---|---|---|---|---|---|
| Essentialis (Soleno) | Diazoxide choline, extended release | Prader-Willi hyperphagia, obesity | Approved in the US as Vykat XR (Mar 2025) | 30 | Diazoxide is known to cause excess hair growth. An approved opener with long-term safety data. |
| Mayo Clinic | Diazoxide and cromakalim prodrugs, eye drops | Glaucoma | Academic patents (stage not checked) | 3 | Shows local KATP opening from a topical product, the property a scalp product needs. Same idea as Qlaris QLS-111 (positive Phase 2, 2025). |
| Rhythm Pharmaceuticals | New KATP potentiator series | Congenital hyperinsulinism | Patent filings 2023–25 (stage not checked) | 6 | Fresh KATP chemistry from a commercial rare-disease company; channel selectivity not disclosed. |
| Salzman Group | Guanidine KATP openers | Pulmonary hypertension | Patent filings 2020 (stage not checked) | 3 | Guanidine openers, the chemical class of BMS's discontinued hair candidate naminidil. |
| Sedogen | Diazoxide (use patents) | Prader-Willi, low metabolic rate | Patent filings 2019–26 (stage not checked) | 6 | Second diazoxide position to clear for any diazoxide-based hair product. |
| Tenax Therapeutics | Levosimendan (also opens KATP) | Pulmonary hypertension with HFpEF | Patent filings 2020–24 (stage not checked) | 5 | Systemic cardiovascular use; mainly a benchmark for KATP safety, low hair relevance. |
Funding · public grants since 2022
1,177 funded projects screened, 106 relevant to hair loss, worth about $37.5 million. Amounts converted to US dollars at approximate rates.
106 relevant projects
$37.5M total funding
0 on minoxidil itself
1 on KATP channels in the follicle
8 with a company involved
| Organisation | Project | Funder · start | US$ | Note |
|---|---|---|---|---|
| Geneus Biotech, Biofabics, Respilon | Up-scaled production of artificial hair follicles | Horizon Europe · 2022 | 4.37M | Follicle manufacturing platform |
| Luminate Medical | LILY: preventing chemotherapy-induced hair loss | Horizon Europe · 2023 | 2.70M | Device company as lead |
| University of Huddersfield, Paxman | Scalp cooling: increasing patient access | UKRI · 2022 | 0.50M | Industry co-funded |
| HairClone | Cell-produced treatments for follicle stimulation | UKRI · 2023 | 0.31M | Licensable asset proposed |
| Lybra Bio | Microneedle expansion of skin regulatory T cells (2 awards) | NIH and NSF SBIR · 2025 | 0.61M | Alopecia areata, small-business grants |
| Rush River Research | Thermoelectric scalp cooling | NIH SBIR · 2025 | 0.31M | Small-business grant |
What it means
Synthesis · what it means
All nine sources side by side, the opportunities they point to, and the same story told for the person in the mirror.
Triangulation · nine AcademicLabs datasets
The same eight topics counted across patents, company profiles, news, publications, grants, new trials, every alopecia trial on record and six years of outcome papers. Patents and science barely overlap: what companies protect is not what researchers study, test or the press covers.
| Topic | Patents (inventions) n=487 | Companies n=579 | News events n=228 | Publications n=346 | Grants n=106 | Trials 2026+ n=72 | All alopecia trials n=1515 | Outcome papers 2020–26 n=209 |
|---|---|---|---|---|---|---|---|---|
| Oral or sublingual minoxidil | 6% 31 | 5% 30 | 6% 14 | 8% 28 | 0 | 4% 3 | 3% 42 | 4% 8 |
| Topical antiandrogens | 6% 30 | 3% 15 | 2% 4 | 3% 11 | 0 | 1% 1 | 2% 34 | 3% 7 |
| Alopecia areata | 5% 24 | 6% 34 | 33% 76 | 31% 107 | 24% 25 | 18% 13 | 29% 438 | 36% 76 |
| JAK and immune pathways | 2% 10 | 1% 7 | 25% 58 | 27% 95 | 9% 10 | 10% 7 | 12% 182 | 26% 54 |
| Cells, exosomes, PRP | 3% 17 | 15% 88 | 5% 11 | 17% 60 | 26% 28 | 10% 7 | 12% 184 | 11% 23 |
| Devices and light | 9% 44 | 21% 122 | 10% 23 | 12% 41 | 12% 13 | 10% 7 | 8% 123 | 7% 15 |
45 inventions in the oral patent theme, 110 VeraDermics filings, $256 million raised, three Phase 3 programs. Against that: 22 papers in 2026 with one small randomized trial, no grant, and 42 trials on record, mostly investigator-led and half without a stated dose. The published head-to-heads show the pill equals the liquid. New trials add Eurofarma's two Phase 3s and a sublingual Phase 2. VeraDermics' Phase 3 data in 536 men will set the evidence standard, and NYU, Lahey, MGB and Sinclair are the groups prescribers follow.
A third of news events and publications, a quarter of grants, 29% of all alopecia trials and 36% of outcome papers, but only 5% of minoxidil inventions. Four approved JAK inhibitors and a $2.2 billion acquisition set the bar, and the relapse data show what a chronic hair drug looks like.
22 inventions name SULT1A1 or sulfotransferase. No news event, no 2026 publication and no grant does. The only clinical evidence, a 2014 response-test trial and a 24-patient booster trial in 2021, comes from the patent holder, Applied Biology. Precision minoxidil is protected but not validated: a gap a clinical study could close.
One grant worth about $28,000, no publication testing channel subtypes, no news and one minoxidil invention. Combined with 6 of 565 opener patents naming hair, the white space is confirmed by every source.
A quarter of grants, 17% of papers, 15% of companies and 184 trials, yet 3% of minoxidil inventions. Fewer than 1 in 10 of those trials is placebo-controlled, and no drug developer runs an exosome trial: much of the activity is clinics selling procedures.
6% of inventions, with Kintor and Cosmo reporting positive Phase 3 data and Dayspring's foam succeeding in Phase 2. Few independent papers yet, so company data will shape the narrative.
Eurofarma filed in 2022, then nothing in news until two Phase 3 trials appear for 2027. Applied Biology registered 12 trials since 2014, five of them withdrawn, with two clinical papers and a silent press.
Pelage has no filings in these patent searches, yet four news events and three trials: a completed Phase 2 in 2024, then men and women in 2026. Its IP sits outside minoxidil.
VeraDermics stacks 104 patent records in 2025 and 2026 on 16 news events and four Phase 2 and 3 trials, but no clinical paper yet: its evidence is still company data. Kintor shows ten trials since 2019 behind pyrilutamide; Eli Lilly a dozen sponsored trials and nine papers with Lilly authors.
| Company | Stage | Patents | News | Papers 2026 | Clinical papers | Grants | Trials |
|---|---|---|---|---|---|---|---|
| Oral minoxidil 3 companies | |||||||
| VeraDermics | Phase 3 | 110 | 16 | 4 | |||
| Samson Clinical | Phase 3 | 15 | 2 | 7 | 19 | 6 | |
| Eurofarma | Phase 3 | 3 | 3 | ||||
| Topical minoxidil 3 companies | |||||||
| Kenvue / J&J (Regaine) | Not disclosed | 66 | 4 | 10 | |||
Hot zones
45 inventions · 174 filings Fastest-rising
Low-dose oral minoxidil moved from off-label practice to proprietary products. VeraDermics claims modified-release tablets of about 5–20 mg (5 mg and 9 mg strengths) that lower peak exposure versus immediate release, backed by over 100 US continuation filings. Others claim oral use in alopecia areata, responder prediction, fixed oral combinations with finasteride, and national formulations in Brazil and China.
Clinical context: VDPHL01 Phase 3 Study 304 (536 men) met both co-primary endpoints on 19 Oct 2026, with +28.6 (once daily) and +36.4 (twice daily) hairs/cm² versus +6.6 on placebo at month 6. On 9 Nov 2026, 12-month Study 302 data (519 men) showed the gains hold or grow with continued use: +43.9 hairs/cm² on twice daily and +29.7 on once daily at month 12, with no cardiac safety signal and no adverse-event dropouts in months 6 to 12. The program has no head-to-head against topical minoxidil. Outside the US, Samson Clinical (sublingual minoxidil, last patient visit May 2026) and Eurofarma (oral N1087) are also in Phase 3, and several Indian brands already sell minoxidil tablets. The wider trial record holds 42 oral minoxidil trials (33 since 2023, half without a stated dose), and the published head-to-heads find low-dose pills equal to the liquid on hair density. VDPHL01 doses higher and twice daily works best, so its edge may be efficacy as well as convenience, but no trial compares it with topical minoxidil.
105 inventions · 229 filings New entrants 2024–26
The largest combination theme. Finasteride dominates historically; dutasteride, spironolactone and high-strength (10–20%) minoxidil blends follow. The new wave pairs minoxidil with next-generation topical androgen-receptor blockers whose owners are now in late-stage trials.
Clinical context: Cosmo reported positive 12-month Phase III clascoterone data in AGA (Apr 2026) and targets US filing in early 2027. Kintor presented Chinese Phase III data for KX-826 (pyrilutamide) in May 2026 and plans a Phase III of KX-826 with minoxidil. News adds a third: Dayspring Pharma's CG2001 minoxidil plus finasteride foam met its Phase 2 endpoint in China (Apr 2026), while the MHRA strengthened oral finasteride warnings (May 2026), a tailwind for topical antiandrogens.
135 inventions · 263 filings Mature
The incumbent playground. Minoxidil is poorly soluble and crystallises on the scalp, so OTC owners patent solvent systems, anti-precipitation additives, containers and aerosols. Taisho and Rohto file every year for the Japanese market; Kenvue (J&J) built its foam and gel polymer estate up to 2021.
34 inventions · 54 filings Niche, steady
Minoxidil only works where scalp sulfotransferase (SULT1A1) converts it to minoxidil sulfate. A small group patents tests that predict response, adjuvants that raise conversion, and even follicle microbes that secrete the enzyme.
Clinical context: the trial record holds one response-testing study (Applied Biology, 2014) and one 24-patient booster trial (2021, 75% vs 33% regrowth at 60 days) with Applied Biology authors. No independent validation, so a well-designed study would be first.
61 inventions · 109 filings 47 carrier inventions · 82 filings
Microneedling, powered needling, light and multi-modal scalp devices pair with topical minoxidil, while carrier patents chase follicle targeting and slower release. Academic groups are active here and often license.
Clinical context: 87 laser and light trials and 36 microneedling trials are on record, but only 8% and 3% are placebo-controlled. Results are modest and mixed (an LED cap beat sham only when arms were pooled), so the device that runs a proper sham-controlled trial can stand out.
54 records · 43 inventions Mostly expired
First-wave KATP opener series from J&J (benzopyrans, coumarins, cyclobutenediones) and Abbott listed hair loss among their uses between 2000 and 2009; NeuroSearch did the same for its calcium-activated channel modulators. None became a hair product. Recent hair-focused filings are few and take other angles: BK channel openers, an oxytocin plus KATP opener blend, and a SUR2B/Kir6.1 blocker against the body-hair side effect of minoxidil.
Why the blocker matters: excess body hair is the main cosmetic side effect of oral minoxidil (9% of patients on twice-daily VDPHL01 in Phase 3), so demand for side-effect management grows with the oral market.
24 inventions · 61 filings Cooling
Pairing minoxidil with latanoprost or bimatoprost peaked in 2012–21. Aneira keeps a large latanoprost–minoxidil estate alive, and Triple Hair claims a three-active blend with finasteride.
Clinical context: Allergan ran bimatoprost Phase 2 trials in men and women from 2010 to 2016 and dropped the program; its PGD2 blocker setipiprant failed against placebo. Prostaglandin analogs fell from 2.4% of trial starts in 2010–19 to 0.2% since 2023, now mostly Iranian investigator studies.
Open space
Only 5 minoxidil inventions claim a new compound, and just 1 of 77 recent KATP opener patents names the Kir6.1/SUR2 subtype minoxidil acts on. Angfa's 2020 filing uses that same subtype to block unwanted hair, which supports it as the hair target. A subtype-selective opener without blood-pressure effects is open ground. Science agrees: one small Japanese grant and no 2026 paper look at channel subtypes in the follicle. The human genetic evidence (Cantú syndrome, where an over-active SUR2/Kir6.1 channel causes excess hair) sits with channel scientists such as Colin Nichols, outside the hair field.
Diazoxide (approved as Vykat XR in 2025) is known to cause excess hair growth, and Mayo's topical diazoxide and cromakalim prodrugs show that local KATP opening works in the eye. Licensing such an asset for scalp use is a shorter route than new chemistry. Expired first-wave opener series are free prior art to build on.
271 of 373 inventions name no specific condition. Alopecia areata (named in 24), chemotherapy-induced loss (9) and female or postpartum loss (7) are thinly covered, as are eyebrows and lashes (1).
Injectables (5), patches (3) and microneedle systems (8) are emerging, with UPenn's 2024 hydrogel and 2026 patch as recent academic filings open to licensing. The clinical case is strong: hair drugs are maintenance therapies (80% of JAK responders relapse on stopping; minoxidil gains fade too), so anything that makes years of use easier has value, as Absci's 65-day half-life antibody shows.
Sulfotransferase (SULT1A1) activation and responder testing appear in 34 inventions but sit with small players (Follea, Applied Biology, Caring Brands). Pairing a responder test with the new oral products is a logical next claim. No 2026 paper or grant has validated one, and the only trials (a 2014 test study and a 24-patient booster trial) come from Applied Biology itself: an independent study would be first.
The 2026 papers on oral minoxidil in women are retrospective (spironolactone combinations, oral versus topical, quality of life), and VeraDermics' female Study 207 is Phase 2. Eurofarma (MINORA-WOMEN, Phase 3) and Pelage (PP405, Phase 2) have now registered female trials, so the window to lead in women is narrowing. Across all alopecia trials, women-only pattern-hair-loss trials fell from 30% to 17% of starts.
309 trials combine minoxidil with microneedling, PRP, lasers or botulinum toxin, almost all small, open and investigator-led, so every add-on still rates "mixed" or "limited". A company that runs one blinded, adequately sized trial of a standardised combination would own the claim, and the clinic channel that sells it.
Anyone developing oral or modified-release minoxidil must map the VeraDermics claims (5–20 mg, 5 and 9 mg strengths, release profiles, exposure limits) before formulating.
Patient view · in plain words
The whole landscape, translated for the person in the mirror. No jargon: just what is going on, what is coming, and what we would do.
1 · What's going onA hormone called DHT slowly makes some hair roots smaller. Hairs get thinner and shorter, and the hairline moves back. It runs in families and about half of all men notice it by 50.
The good news: a shrunken root stays alive for years, so it can often be saved. A root that has been gone for a long time usually cannot come back.
2 · Where it's going soonA once-a-day minoxidil pill passed two big tests in 2026 and could be approved around 2027 or 2028. Creams that block the hormone only in the scalp (not the whole body) also passed big tests.
Later come treatments that wake up sleeping roots, and much later, lab-grown hair roots.
3 · What we would doSee a skin doctor (dermatologist) and ask about the "stop and grow" combo: one medicine that stops the hormone and one that helps hair grow.
Take a photo every 3 months, judge after 6 to 12 months, and keep going: stopping undoes the gains. When the new options arrive, you can switch or add.
The "stop" button: finasteride. A daily pill that blocks DHT, the hormone that shrinks hair roots. A spray version is already sold in parts of Europe.
The "grow" button: minoxidil. A liquid or foam on the scalp, or a small daily pill a doctor can prescribe. It wakes up roots and makes hairs thicker.
Together they work better than either alone. Some doctors add microneedling (tiny needles that boost the effect). A hair transplant moves roots around; it does not stop the loss, so you still need medicine.
Finasteride: in a big two-year study, 83 out of 100 men stopped losing hair, against 28 out of 100 on a dummy pill. 66 out of 100 saw more hair.
Minoxidil: most men see the loss slow down, and many see new hair after 4 to 6 months. In the 2026 tests of the new long-acting pill, men grew about 22 to 30 more hairs per square centimetre than with a dummy pill, within 6 months. After a full year, men on the twice-a-day dose had about 44 more hairs per square centimetre than when they started, and the hair kept improving as long as they kept taking it.
Pill or liquid? When the two were tested side by side, they grew about the same amount of hair. The pill is simply easier to take every day, and a treatment you keep using is the one that works.
Extras like PRP, laser caps and microneedling: some studies show a bit more hair, others show none, and most were small. They cost more. Use them on top of the basics, never instead.
A tip: be careful with clinics that only show before-and-after photos. Almost every study without a comparison group says a treatment works; fair tests that compare against another group are much less rosy.
Set the right goal: think "keep what I have, and get some back", not "a full head of hair again". Some shedding in the first weeks is normal and a sign it is starting to work.
Side effects: a small number of men get sexual or mood side effects from finasteride; the UK regulator strengthened its warnings in 2026, so talk this through with your doctor. Minoxidil pills can cause extra body hair, ankle swelling or a faster heartbeat in some people.
Yes, but not right away. The next two years bring easier versions of today's medicines. The really new ones try to wake up "sleeping" hair roots instead of just protecting tired ones.
One of them (PP405) started a big test in October 2026, and about five others are in early tests with people. If they work, they could arrive around 2029 to 2031. Most early medicines do not make it: since 2007, at least nine "new" hair-loss medicines were tested in people and then stopped. The new ones will also work best on roots you still have. So: protect your hair now.
No. Today's treatments protect the roots you still have. The new ones will mostly work on those same roots, often in the same way, just more conveniently. Waiting two years can cost you roots that no future medicine brings back. Starting now keeps your options open, and may mean a smaller transplant later, or none.
In women, hair usually thins over the top and the parting gets wider, while the front hairline stays. Genes and hormones play a role.
Check first: low iron, thyroid problems, stress, a new medicine or a recent pregnancy can also cause shedding. A simple blood test helps find the cause.
2 · Where it's going soonToday, women mostly use medicines first tested in men. That is changing: a big test of a minoxidil pill in 556 women reports results in the first half of 2027, and another big test in women starts in 2027.
If the results are good, approved pills for women could follow around 2028 or later.
3 · What we would doSee a skin doctor and ask for blood tests. Start with minoxidil; if it is not enough, ask about a low-dose minoxidil pill or spironolactone.
Tell your doctor if you might get pregnant: some hair medicines are not safe then. Judge after 6 to 12 months, and keep going.
Minoxidil liquid or foam: the approved treatment for women. It helps roots grow thicker hair.
Low-dose minoxidil pill: many doctors prescribe it when the liquid is impractical or not enough. It is not specifically approved for hair yet.
Spironolactone: a pill that calms the hormones that shrink hair roots. Not to be used during pregnancy. Finasteride is usually not used by women who could get pregnant.
Minoxidil helps most women keep their hair, and many see thicker hair after about 6 months.
The pills are mostly backed by doctors' records rather than big trials so far. In one 2026 study of 432 women taking spironolactone and a low-dose minoxidil pill, about 1 in 3 had a side effect, mostly mild; about 1 in 8 noticed extra facial or body hair.
New in 2026: in a study comparing two hormone-blocking pills, bicalutamide grew a little more hair than spironolactone. Neither is officially approved for hair, so this is a choice to make with your doctor.
Extras like PRP and laser caps: results are mixed and most studies were small. Use them on top of the basics, not instead.
Set the right goal: fuller hair over the top and a narrower parting, not a different head of hair.
Yes, but not right away. First come pills tested properly in women (results from 2027). After that, new medicines that try to wake up "sleeping" hair roots; one of them (PP405) is already being tested in women.
These newer ones could arrive around 2029 to 2031 if they work. Hair you keep now is hair they can help.
No. The new pills are better-tested versions of minoxidil, which you can already use today with a doctor. Hair saved now is hair you keep. Starting early also tells you and your doctor what works for you.
Men: finasteride plus minoxidil. Women: minoxidil, with spironolactone or a low-dose pill if needed. Microneedling can help.
Very soon · 2027 to 2028 Easier and better-testedAn approved once-a-day minoxidil pill, scalp-only hormone blockers, and minoxidil under the tongue, if regulators agree.
Soon · 2029 to 2031 Waking sleeping rootsRoot re-starters like PP405, more treatments tested in women, and maybe a test that shows if minoxidil will work for you.
Later · 2032 and beyond Making new rootsLab-grown hair roots, cell and gene treatments, and hair-only versions of minoxidil-like medicines. Transplants become smaller or unnecessary.
Dates are estimates based on 2026 trial results and company plans; trials can fail or take longer. This page is general information, not medical advice: talk to a dermatologist before starting or stopping any treatment.Data and method
Method & next steps
Six AcademicLabs runs that would deepen this landscape.
Clinical trials Completed and stopped trials: results and reasons
Follows up the 573 completed and 75 stopped alopecia trials analysed in this report: whether results were posted or published, what the primary result was, and why programs stopped. Turns the trial record into a readout calendar and a database of what failed and why.
TopicHair-loss conditions, minoxidil and its analogs, potassium channel openers
ScopeStatus: completed, terminated, withdrawn or suspended All years Search title, summary and condition
Patents Chinese patents
Adds the Chinese patent filings now being loaded into AcademicLabs. China leads 2026 hair papers (127 of 346) and Dayspring's minoxidil-finasteride foam surfaced only through news, so Chinese formulators, universities and hospitals are likely under-counted today.
TopicMinoxidil and potassium channel openers with hair terms, in Chinese and English
ScopePatent office: China Published 2015 to 2026
Publications Publications 2018 to 2025, reviews included
Builds the full evidence base behind oral, sublingual and topical minoxidil and their combinations, including consensus statements and safety series, beyond the 2026 snapshot.
TopicMinoxidil, its analogs and openers with hair terms, all article types
ScopePubMed Published 2018 to 2025 All publication types Search title and abstract
Researchers Researchers: practice leaders and rising stars
Profiles the clinicians who generate minoxidil evidence but sit below the citation cut-off (NYU, Lahey, Mass General Brigham, Sinclair) and the next generation of hair-loss investigators.
TopicHair-loss conditions and hair biology, or minoxidil with hair terms
ScopePublication date 2024 to 2026 h-index 20 to 75
Research groups Research groups: potassium channel science and hair
Maps the channel scientists who hold the human genetic evidence (Cantú syndrome) that the minoxidil target drives hair growth, as partners for a hair-selective opener.
TopicCantú syndrome and ATP-sensitive potassium channel science
ScopeResearch groups Publication date 2021 to 2026
Companies Companies: hair-loss drug developers beyond minoxidil
Completes the competitive set with every company developing a hair-loss drug, whatever the mechanism (Pelage, Kintor, JAK owners, cell therapy), worldwide.
TopicHair-loss drug development of any mechanism
ScopeAll countries Active companies Pharmacies and clinics excluded
Data: AcademicLabs patents (three searches), companies (three runs), news, publications, clinical study publications, funded projects, clinical trials (two searches) and researchers, each with AI analysis, exported 4 to 8 Nov 2026. Patent records and profiles are viewable without signup on AcademicLabs.com.
This report is an example of what AcademicLabs builds. Our AI reads every record and stays grounded in the source: no web searches, no facts from model memory, and every figure traceable to the patents, trials, papers and profiles behind it. We make the same for any disease, target, technology, modality or country.
Contact usHow to cite. AcademicLabs (2026). Minoxidil Landscape 2026. Arne Smolders. https://academiclabs.com/research-reports/minoxidil-landscape-2026. Data as of 8 November 2026. Licensed CC BY 4.0.
VeraDermics leads with VDPHL01, a modified-release oral minoxidil (8.5 mg). It met its Phase 3 endpoints in October 2026, and 12-month data from Study 302 in November 2026 showed +43.9 hairs/cm² on twice-daily dosing versus +29.7 once daily. VeraDermics filed 109 patent applications on that one invention, with patent term to 2043, and runs a 556-woman Phase 3. Samson Clinical (sublingual SAM-002), Eurofarma (oral N1087, two Phase 3 trials from 2027, including MINORA-WOMEN) and Business Life Health are also in late-stage trials.
Not in the published evidence so far. In four head-to-head trials, low-dose oral minoxidil (0.25 to 5 mg) never beat topical minoxidil on hair density, and only 1 of 22 oral minoxidil papers published in 2026 is a randomized trial. VDPHL01 doses higher and has been tested against placebo only, so whether a higher-exposure pill beats the liquid is still open.
Mostly reformulation and combination. Minoxidil itself is central in 279 of 373 core inventions; aminexil appears in 7, minoxidil sulfate in 1, and only 5 claim a new chemical entity. 177 inventions are formulation or delivery systems and 113 combine actives, most often with finasteride (76). 88% mention no supporting data in their abstract or claims.
By filings, VeraDermics dwarfs everyone: 110 applications on two inventions between 2023 and 2026. By inventions, Japanese OTC players and Follea lead. Taisho and Rohto have refined topical minoxidil almost every year for 15 years, and Cosmo (clascoterone) and Kintor (pyrilutamide, KX-826) filed minoxidil combinations as their own antiandrogens neared approval filings.
Pelage's PP405, which aims to restart dormant hair stem cells (positive Phase 2, Phase 2/3 dosing from October 2026, with a female study), two prolactin receptor antibodies (Absci's ABS-201 and Hope Medicine's HMI-115) and a thyroid hormone mimetic. Nine earlier mechanisms for pattern hair loss entered trials between 2007 and 2020, from Wnt activation and prostaglandins to peptides and cell injections, and none reached a filing.
Weak. Of 205 hair-treatment outcome papers since 2020, 93% of uncontrolled studies report benefit, against 55% of randomized trials and 46% of trials against an active treatment. Only 6% of PRP trials, 9% of exosome trials and 8% of device trials are placebo-controlled.
In different places. The US holds 40% of minoxidil inventions and leads 42% of company-run trials. India leads 21% of all alopecia trials and the Middle East and Africa 16%, with 1% and 2% of inventions. Europe and South Korea hold 46% of hair-loss drug developers.
Less than before. Only 17% of pattern-hair-loss trials starting since 2023 enrol women only, down from 30% in 2016 to 2019. VeraDermics' 556-woman Phase 3, Eurofarma's MINORA-WOMEN and Pelage's female PP405 study are the main openings.
Barely. Only 6 of 565 relevant potassium channel opener patents since 2019 propose a hair use, while 46% target Kv7 channels for brain disorders. Across $37.5 million of public grants, one project of about $28,000 studies KATP channels in the follicle, and none of the 1,515 relevant alopecia trials tests a new opener.
JAK inhibitors went from case reports in 2014 to four approved drugs for alopecia areata, with 21% to 55% of patients regaining most hair versus 1% to 9% on placebo. But 80% of responders relapse after stopping, so hair drugs behave as maintenance therapies, and convenience and long-term safety decide the market.
From nine AcademicLabs datasets exported 4 to 8 November 2026: patents (three searches), companies, news, publications, funded projects, clinical trials (new and all years), clinical study papers since 2020 and researchers. AcademicLabs AI read a recent, relevant subset of each record by record, with no web search or model memory. Counts and charts were computed in code and cross-analysed across sources.
Yes. The figures are licensed CC BY 4.0: free to reuse with credit “Source: AcademicLabs” and a link to https://academiclabs.com/research-reports/minoxidil-landscape-2026.
Yes. AcademicLabs builds landscapes like this for any disease, target, technology, modality or country, from €1,000 to €10,000 depending on scope, and offers monthly briefings. You can also build them yourself with AcademicLabs.
How to cite. AcademicLabs (2026). Minoxidil Landscape 2026. Arne Smolders. https://academiclabs.com/research-reports/minoxidil-landscape-2026. Data as of 8 November 2026. Licensed CC BY 4.0.